DoxyPEP: Real Individual Benefit Against a Population-Level Bet
He is asking for a pill that would meaningfully lower his own infection risk. The same evidence shows it may come at a cost to people he will never meet.
Devon A., a 30-year-old graphic designer, has had three separate bacterial STI diagnoses — two chlamydia infections and one early syphilis — over the past fourteen months despite what he describes as consistent condom use, and came to this visit specifically asking about doxycycline post-exposure prophylaxis after hearing about it from friends in his social circle. He is otherwise healthy, takes no other regular medications, and has no known drug allergies; his recurrent-infection pattern places him closely within the population the DoxyPEP trial (Luetkemeyer et al., 2023) actually enrolled — men who have sex with men and transgender women with a bacterial STI in the preceding year, exactly his own profile.
DoxyPEP found large reductions in incident chlamydia and syphilis among participants taking a single 200mg dose within 72 hours of condomless sex, alongside a real but distinctly smaller effect against gonorrhea, roughly a 55% reduction — a gap the trial’s own investigators attributed at least partly to existing tetracycline resistance already present in circulating gonococcal strains. Current CDC guidance, updated to reflect this evidence, now recommends offering doxyPEP to patients matching his risk profile, while also naming an open, unresolved concern shared broadly across the field: what regular, population-level doxycycline exposure for STI prevention does to resistance patterns over time, in gonorrhea and in the broader ecosystem of bacteria exposed along with it.
What distinguishes his own three-episode history from a hypothetical risk calculation is that each of his prior infections was treated with a full therapeutic antibiotic course, while doxyPEP’s dosing is a single, comparatively low exposure taken intermittently around specific encounters — a genuinely different selection-pressure profile than continuous prophylactic dosing would create, though not a zero one. That distinction is real but it is not evidence: DoxyPEP measured resistance over twelve months in a few hundred participants, which is long enough to detect the tetracycline-resistant strains it did detect and nowhere near long enough to characterize what population-scale use does over years. The resistance concern in his case is therefore not a finding being weighed against his benefit — it is an acknowledged gap in what has been measured, and the honest framing to him is that the individual number is known and the collective one is not.
Sexual health clinic, prevention counseling visit
His risk profile matches the trial population closely, and the individual benefit shown was substantial — a real reduction in chlamydia and syphilis specifically, with three episodes of his own in the past fourteen months as direct evidence this isn’t a hypothetical risk for him. I’d offer doxyPEP today.
I want to name the part of the trial that doesn’t get repeated as often — the gonorrhea protection was meaningfully blunted, specifically because of existing tetracycline resistance. Widespread doxyPEP use raises a real concern about accelerating that resistance further, in gonorrhea and in off-target bacteria exposed alongside it every time this is used. That’s a genuine population-level cost, not a footnote, and it falls on people beyond just him.
I don’t think either of you is wrong, and I don’t think this needs to be resolved by picking a side. I’d offer it, with explicit informed consent that names both things honestly — the real individual benefit he’s asking for, and the real collective resistance concern the pharmacist is raising — plus routine STI and resistance-pattern monitoring built into his follow-up, so if the local picture shifts, we catch it rather than assume the trial’s numbers hold indefinitely.
Agreed: doxyPEP offered and started, with informed consent documenting the discussion of individual benefit versus resistance concern explicitly, and STI screening with resistance-pattern tracking scheduled every three months rather than the standard annual interval.
Not agreed as a settled question: the stewardship pharmacist continues to advocate for closer population-level surveillance before doxyPEP becomes routine practice rather than individualized counseling, a broader policy position the other two voices did not take a stance on in this individual patient encounter.